Skip to main
MDXG
MDXG logo

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc. has demonstrated strong revenue growth, reporting $98.6 million in the most recent quarter, which reflects a year-over-year increase of approximately 13%, supported by significant contributions from both its wound portfolio and surgical segments. The company's positive trajectory is further underscored by an upward revision in the 2025 revenue estimate to $387.3 million, up from a previous estimate of $374.0 million, largely attributed to robust second-quarter performance and expanding surgical business capabilities. While selling, general, and administrative expenses rose about 16% year-over-year to $64.2 million, this investment in sales and legal support may enhance future revenue generation potential.

Bears say

MiMedx Group Inc. reported a decline in gross margin to approximately 81% from 83% in the second quarter of 2025, attributed to production variances and an unfavorable product mix. Despite the company's long-term guidance of achieving low double-digit year-over-year revenue growth and an adjusted EBITDA margin above 20%, concerns linger regarding potential negative changes to reimbursement rates from CMS, which could significantly affect its business. Given these factors, the financial outlook for MiMedx Group appears challenging, highlighting risks associated with profitability and revenue sustainability.

MiMedx Group (MDXG) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 1 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.